CSF PFDN5-alpha Reactivity Detection for CNS Leukemia Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing central nervous system (CNS) involvement in B-cell acute lymphoblastic leukemia (B-ALL) rely on prophylactic intrathecal drug injections, which can cause significant side effects, and there is a need for a more accurate prediction method to avoid unnecessary treatment.
Innovation Solution
A method involving the detection of reactivity of cerebrospinal fluid (CSF) with PFDN5-α using techniques like far western blot, pull-down assay, or ELISA to determine the likelihood of CNS leukemia, allowing for personalized treatment strategies based on CSF reactivity profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prophylactic intrathecal drug injections are administered to prevent CNS involvement in B-ALL patients, then the risk of CNS leukemia is reduced, but significant side effects occur including secondary neoplasms, neurocognitive dysfunction, and endocrine diseases
Solution Approach 1:
The patent applies preliminary action by detecting CSF reactivity to PFDN5-α before initiating prophylactic treatment. This early detection allows identification of patients at high risk for CNS leukemia, enabling targeted prophylaxis only for those who need it, thereby avoiding unnecessary exposure to treatment side effects while maintaining prevention effectiveness for high-risk patients
Solution Approach 2:
The patent implements local quality by differentiating treatment approaches based on individual patient risk profiles determined through CSF reactivity testing. Instead of uniform prophylactic treatment for all B-ALL patients, the method applies treatment selectively to specific subgroups (those with positive CSF reactivity to PFDN5-α), optimizing the balance between prevention and minimizing harm
2Reliability
If prophylactic treatment is administered to all B-ALL patients, then CNS involvement is prevented, but unnecessary treatment is given to patients at low risk
Solution Approach 1:
The patent applies partial action by administering prophylactic treatment only to the portion of patients who demonstrate positive CSF reactivity to PFDN5-α, rather than treating all patients equally. This selective approach ensures adequate prevention coverage for high-risk individuals while avoiding unnecessary treatment in low-risk patients, optimizing resource allocation
3Object-generated harmful factors
If CSF reactivity testing for PFDN5-α is performed to identify patients at risk, then unnecessary prophylactic treatments are avoided, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent replaces complex mechanical diagnostic procedures with a biochemical assay approach. Instead of relying on invasive neurological examinations or complex imaging studies, the method uses CSF reactivity testing with PFDN5-α, which can be performed using standardized laboratory techniques, thereby simplifying the diagnostic workflow while maintaining high accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables early detection of CNS leukemia, reducing unnecessary prophylactic treatments and their side effects by accurately identifying patients at risk, thereby improving treatment efficacy and minimizing adverse reactions.
Implementation Method 1
detecting reactivity of CSF with the PFDN5-α and determining the status of proliferation of leukemia in the patient depending on the level of reactivity
Implementation Method 2
Detecting reactivity of CSF with the PFDN5-α may comprise testing using far western blot test, a pull down assay, an ELISA test or immunoprecipitation
Data Source
AI summary
A method of managing treatment in a patient with B-cell acute lymphoblastic leukemia (B-ALL) for central nervous system (CNS) leukemia is disclosed. The method comprises obtaining cerebrospinal fluid (CSF) from the patient, obtaining a cell proteome including PFDN5-α from the patient, detecting reactivity of CSF against the PFDN5-α, comparing reactivity profile of CSF against the PFDN5-α at diagnosis and during treatment, and determining the status of proliferation of leukemia in the patient depending on the comparison. The method further comprises treating the patient for CNS leukemia based on the status of proliferation.